Sat, Jul 12, 2014, 7:02 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • scistats scistats Jul 13, 2013 2:58 PM Flag

    Big Red to give free pony rides on the Sanofi lawns August 1st. Bring the whole family!

    On July 22, 2009, CombinatoRx, Incorporated ("CombinatoRx") and Fovea Pharmaceuticals SA ("Fovea") amended and restated their Amended and Restated Research and License Agreement, dated as of June 12, 2007 (the "Amended Agreement"). Under the Amended Agreement, CombinatoRx has granted Fovea an exclusive worldwide license to certain drug combinations to treat allergic and inflammatory diseases of the front of the eye. Fovea has advanced one such combination, Prednisporin (FOV-1101), through a Phase 2a proof-of-concept clinical trial for allergic conjunctivitis. For these licensed combinations, CombinatoRx has received payments totaling $1.0 million and is eligible to receive up to $24.75 million in development and regulatory milestone payments for each combination successfully developed by Fovea, an additional $15.0 million milestone payment for the approval of a combination in a specified additional indication, and in the event these exclusively licensed combinations are licensed by Fovea to a third party, commercialization milestones of up to an additional $25.0 million. CombinatoRx is also eligible to receive royalties for each product commercialized by Fovea in connection with the Amended Agreement.

    Under the Amended Agreement, Fovea will also continue to conduct, at its own expense, preclinical and clinical development for certain ophthalmic indications of other combination drug candidates it has selected from CombinatoRx's portfolio of product candidates. Fovea is obligated to develop these selected combination candidates through the end of Phase 2b clinical trials. CombinatoRx and Fovea jointly own new intellectual property and data generated by Fovea regarding these selected combination candidates through Phase 2 clinical trials. CombinatoRx retains the rights to develop and commercialize the combination candidates licensed to Fovea in North America and certain other countries, and CombinatoRx granted Fovea exclusive rights to commercialize selected...

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.14-0.02(-1.72%)Jul 11 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.